Proactive anti-inflammatory therapy with colchicine in the treatment of advanced stages of new coronavirus infection. The first results of the COLORIT study

Actuality The course of the novel coronavirus disease (COVID-19) is unpredictable. It manifests in some cases as increasing inflammation to even the onset of a cytokine storm and irreversible progression of acute respiratory syndrome, which is associated with the risk of death in patients. Thus, proactive anti-inflammatory therapy remains an open serious question in patients with COVID-19 and pneumonia, who still have signs of inflammation on days 7–9 of the disease: elevated C-reactive protein (CRP)>60 mg/dL and at least two of the four clinical signs: fever >37.5°C; persistent cough; dyspnea (RR >20 brpm) and/or reduced oxygen blood saturation <94% when breathing atmospheric air. We designed the randomized trial: COLchicine versus Ruxolitinib and Secukinumab in Open-label Prospective Randomized Trial in Patients with COVID-19 (COLORIT). We present here data comparing patients who received colchicine with those who did not receive specific anti-inflammatory therapy. Results of the comparison of colchicine, ruxolitinib, and secukinumab will be presented later.
Objective Compare efficacy and safety of colchicine compared to the management of patients with COVID-19 without specific anti-inflammatory therapy.
Material and Methods Initially, 20 people were expected to be randomized in the control group. However, enrollment to the control group was discontinued subsequently after the inclusion of 5 patients due to the risk of severe deterioration in the absence of anti-inflammatory treatment. Therefore, 17 patients, who had not received anti-inflammatory therapy when treated in the MSU Medical Research and Educational Center before the study, were also included in the control group. The effects were assessed on day 12 after the inclusion or at discharge if it occurred earlier than on day 12. The primary endpoint was the changes in the SHOCS-COVID score, which includes the assessment of the patient’s clinical condition, CT score of the lung tissue damage, the severity of systemic inflammation (CRP changes), and the risk of thrombotic complications (D-dimer) [1].
Results The median SHOCS score decreased from 8 to 2 (p = 0.017), i.e., from moderate to mild degree, in the colchicine group. The change in the SHOCS-COVID score was minimal and statistically insignificant in the control group. In patients with COVID-19 treated with colchicine, the CRP levels decreased rapidly and normalized (from 99.4 to 4.2 mg/dL, p<0.001). In the control group, the CRP levels decreased moderately and statistically insignificantly and achieved 22.8 mg/dL by the end of the follow-up period, which was still more than four times higher than normal. The most informative criterion for inflammation lymphocyte-to-C-reactive protein ratio (LCR) increased in the colchicine group by 393 versus 54 in the control group (p = 0.003). After treatment, it was 60.8 in the control group, which was less than 100 considered safe in terms of systemic inflammation progression. The difference from 427 in the colchicine group was highly significant (p = 0.003).
The marked and rapid decrease in the inflammation factors was accompanied in the colchicine group by the reduced need for oxygen support from 14 (66.7%) to 2 (9.5%). In the control group, the number of patients without anti-inflammatory therapy requiring oxygen support remained unchanged at 50%. There was a trend to shorter hospital stays in the group of specific anti-inflammatory therapy up to 13 days compared to 17.5 days in the control group (p = 0.079). Moreover, two patients died in the control group, and there were no fatal cases in the colchicine group. In the colchicine group, one patient had deep vein thrombosis with D-dimer elevated to 5.99 µg/mL, which resolved before discharge.
Conclusions Colchicine 1 mg for 1-3 days followed by 0.5 mg/day for 14 days is effective as a proactive anti-inflammatory therapy in hospitalized patients with COVID-19 and viral pneumonia. The management of such patients without proactive anti-inflammatory therapy is likely to be unreasonable and may worsen the course of COVID-19. However, the findings should be treated with caution, given the small size of the trial.

1. Mareev V. Yu., Begrambekova Yu.L., Mareev Yu.V. How evaluate results of treatment in patients with COVID-19? Symptomatic Hospital and Outpatient Clinical Scale for COVID-19 (SHOCS-COVID). Kardiologiia. 2020;60(11):35–41. DOI: 10.18087/cardio.2020.11.n1439

2. Johns Hopkins Coronavirus Resource Center. Mortality Analyses. [Internet] Available at: https://coronavirus.jhu.edu/data/mortality

3. Mareev V.Yu., Orlova Ya.A., Pavlikova E.P., Matskeplishvili S.T., Akopyan Zh.A., Plisyk A.G. et al. Combination therapy at an early stage of the novel coronavirus infection (COVID-19). Case series and design of the clinical trial “BromhexIne and Spironolactone for CoronаvirUs Infection requiring hospiTalization (BISCUIT)”. Kardiologiia. 2020;60(8):4–15. DOI: 10.18087/cardio.2020.8.n1307

4. Mareev V.Yu., Orlova Ya.A., Plisyk A.G., Pavlikova E.P., Matskeplishvili S.T., Akopyan Zh.A. et al. Results of an open prospective controlled comparative study on the treatment of new coronavirus infection (COVID-19): Bromhexine and spironolactone for the treatment of coronavirus Infection requiring hospitalization (BISCUIT). Kardiologiia. 2020;60(11):4–15. DOI: 10.18087/cardio.2020.11.1440

5. Mareev V.Yu., Orlova Ya.A., Pavlikova E.P., Akopyan Zh.A., Matskeplishvili S.T., Plisyk A.G. et al. Proactive anti-inflammatory and anticoagulant therapy in the treatment of advanced stages of novel coronavirus infection (COVID-19). Case Series and Study Design: COLchicine versus ruxolitinib and secukinumab in open prospective randomIzed trial (COLORIT). Kardiologiia. 2020;60(9):4–21. DOI: 10.18087/cardio.2020.9.n1338

6. Mareev V.Yu., Orlova Ya.A., Pavlikova E.P., Matskeplishvili S.T., Krasnova T.N., Malahov P.S. et al. Steroid pulse -therapy in patients With coronAvirus Pneumonia (COVID-19), sYstemic inFlammation And Risk of vEnous thRombosis and thromboembolism (WAYFARER Study). Kardiologiia. 2020;60(6):15–29. DOI: 10.18087/cardio.2020.6.n1226

7. FitzGerald JD, Dalbeth N, Mikuls T, Brignardello‐Petersen R, Guyatt G, Abeles AM et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care & Research. 2020;72(6):744–60. DOI: 10.1002/acr.24180

8. Kiselev Yu.Yu., Matveev A.V., Sychev D.A. Current and future use of colchicine in patients with COVID-19. Good Clinical Practice. 2020;4S:71–4. DOI: 10.37489/2588-0519-2020-S4-71-74

9. Tardif J-C, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. New England Journal of Medicine. 2019;381(26):2497–505. DOI: 10.1056/NEJMoa1912388

10. Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ et al. Colchicine in Patients with Chronic Coronary Disease. New England Journal of Medicine. 2020;383(19):1838–47. DOI: 10.1056/NEJMoa2021372

11. Demidowich AP, Davis AI, Dedhia N, Yanovski JA. Colchicine to decrease NLRP3-activated inflammation and improve obesity-related metabolic dysregulation. Medical Hypotheses. 2016; 92:67–73. DOI: 10.1016/j.mehy.2016.04.039

12. Yang M, Lv H, Liu Q, Zhang L, Zhang R, Huang X et al. Colchicine Alleviates Cholesterol Crystal-Induced Endothelial Cell Pyroptosis through Activating AMPK/SIRT1 Pathway. Oxidative Medicine and Cellular Longevity. 2020; 2020:9173530. DOI: 10.1155/2020/9173530

13. Martínez GJ, Celermajer DS, Patel S. The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation. Atherosclerosis. 2018; 269:262–71. DOI: 10.1016/j.atherosclerosis.2017.12.027

14. Brunetti L, Diawara O, Tsai A, Firestein BL, Nahass RG, Poiani G et al. Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19. Journal of Clinical Medicine. 2020;9(9):2961. DOI: 10.3390/jcm9092961

15. Montealegre-Gómez G, Garavito E, Gómez-López A, Rojas-Villarraga A, Parra-Medina R. Colchicine: A potential therapeutic tool against COVID-19. Experience of 5 patients. Reumatología Clínica. 2020; [Epub ahead of print]. DOI: 10.1016/j.reuma.2020.05.001

16. Lu Y, Chen J, Xiao M, Li W, Miller DD. An Overview of Tubulin Inhibitors That Interact with the Colchicine Binding Site. Pharmaceutical Research. 2012;29(11):2943–71. DOI: 10.1007/s11095-012-0828-z

17. Deftereos SG, Giannopoulos G, Vrachatis DA, Siasos GD, Giotaki SG, Gargalianos P et al. Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized with Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial. JAMA Network Open. 2020;3(6): e2013136. DOI: 10.1001/jamanetworkopen.2020.13136

18. University of Oxford. Randomised Evaluation of COVID-19 Therapy. ClinicalTrials.gov Identifier: NCT04381936. Av. at: https://clinicaltrials.gov/ct2/show/NCT04381936. 2021.

19. U.S. National Library of Medicine. Anti-Coronavirus Therapies to Prevent Progression of COVID-19, a Randomized Trial. ClinicalTrials. gov Identifier: NCT04324463. Av. at: https://www.clinicaltrials.gov/ct2/show/NCT04324463. 2020.

20. Tardif J-C, Bouabdallaoui N, L’Allier PL, Gaudet D, Shah B, Pillinger MH et al. Efficacy of Colchicine in Non-Hospitalized Patients with COVID-19. Av. at: http://medrxiv.org/lookup/doi/10.1101/2021.01.26.21250494. 2021.

21. Lomonosov Moscow State University Medical Research and Educational Center. COLchicine Versus Ruxolitinib and Secukinumab In Open Prospective Randomized Trial (COLORIT). ClinicalTrials. gov Identifier: NCT04403243. Av. at: https://clinicaltrials.gov/ct2/show/NCT04403243. 2020.

22. Lagunas-Rangel FA. Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. Journal of Medical Virology. 2020;92(10):1733–4. DOI: 10.1002/jmv.25819

23. Royal College of Physicians. National Early Warning Score (NEWS) 2. 2017. [Internet] Available at: https://www.rcplondon.ac.uk/projects/outputs/national-early-warning-score-news-2

24. Liao X, Wang B, Kang Y. Novel coronavirus infection during the 2019–2020 epidemic: preparing intensive care units—the experience in Sichuan Province, China. Intensive Care Medicine. 2020;46(2):357–60. DOI: 10.1007/s00134-020-05954-2

25. Landray M. Colchicine for non-hospitalised pts with COVID-19. Av. at: https://twitter.com/MartinLandray/status/1354505388582981632?s=08. 2021.

26. Ullah W, Basyal B, Tariq S, Almas T, Saeed R, Roomi S et al. Lymphocyte-to-C-Reactive Protein Ratio: A Novel Predictor of Adverse Outcomes in COVID-19. Journal of Clinical Medicine Research. 2020;12(7):415–22. DOI: 10.14740/jocmr4227

27. Kong M, Zhang H, Cao X, Mao X, Lu Z. Higher level of neutrophil-tolymphocyte is associated with severe COVID-19. Epidemiology and Infection. 2020;148: e139. DOI: 10.1017/S0950268820001557

28. Karataş MB, İpek G, Onuk T, Güngör B, Durmuş G, Çanga Y et al. Assessment of Prognostic Value of Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio in Patients with Pulmonary Embolism. Acta Cardiologica Sinica. 2016;32(3):313–20. DOI: 10.6515/acs20151013a

29. Zhang Y, Wu W, Du M, Luo W, Hou W, Shi Y et al. Neutrophil-toLymphocyte Ratio may Replace Chest Computed Tomography to Reflect the Degree of Lung Injury in Patients with Corona Virus Disease 2019 (COVID-19). Av. at: https://www.researchsquare.com/article/rs-23201/v1. DOI: 10.21203/rs.3.rs-23201/v1. 2020.

30. Feng Z, Yu Q, Yao S, Luo L, Zhou W, Mao X et al. Early prediction of disease progression in COVID-19 pneumonia patients with chest CT and clinical characteristics. Nature Communications. 2020;11(1):4968. DOI: 10.1038/s41467-020-18786-x

31. Vernadsky R.Yu., Medvedeva A.A., Garbukov E.Yu., Sinilkin I.G., Bragina O.D., Zelchan R.V. et al. Single-photon emission computed tomography with 99mTc-1-thio-d-glucose for metabolic breast cancer imaging. Russian Electronic Journal of Radiology. 2019;9(4):82–96. DOI: 10.21569/2222-7415-2019-9-4-82-96

32. Zhao W, Zhong Z, Xie X, Yu Q, Liu J. CT Scans of Patients with 2019 Novel Coronavirus (COVID-19) Pneumonia. Theranostics. 2020;10(10):4606–13. DOI: 10.7150/thno.45016

33. Li R, Liu G, Huang X, Jia C, Xia Z, Song W et al. Dynamic changes in clinical and CT characteristics of COVID-19 cases with different exposure histories: a retrospective study. BMC Infectious Diseases. 2020;20(1):567. DOI: 10.1186/s12879-020-05306-x

34. Kamalov A.A., Mareev V.Yu., Orlova Ya.A., Plisyk A.G., Akopyan Zh.A., Mareev Yu.V. et al. Open comparative controlled trial on use of hydroxychloroquine for treatment of patients with novel coronavirus infection (COVID-19). Kardiologiia. 2021;61(2). DOI: 10.18087/cardio.2021.61(2).n1548